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Background
The general objective has been to generate the genetic vac-
cine vector that assures induction of strong and protective
T-cell and B-cell immune responses against the HIV1. We
have developed Gene Transport Unit (GTU®) plasmid vec-
tor system, which uses bovine papillomavirus type 1 seg-
regation/partitioning and transcription activation
functions provided by the viral E2 protein and E2 mul-
timeric binding sites. The GTU® vectors assure high level,
targeted and extended expression of the viral antigens for
the genetic vaccines.
Methods
We analysed the expression properties of ubiquitous and
epidermis specific GTU® vectors in tissue culture as well as
in various muscle and skin models. Immunological stud-
ies have been performed in different model systems using
GTU® vectors that express HIV antigens.
Results
The antigen expression is more than an order of magni-
tude higher from GTU®  vectors compared to regular
expression vectors. In accordance with GTU®  plasmid
maintenance function, the differences in expression levels
were greater in later time-points. Use of cell-type specific
promoters in GTU® vectors allowed cell-type restricted
expression in differentiating epidermis and other tissues.
The benefits of GTU® vector system were confirmed in
immunological studies in different preclinical animal
models in inducing T-cell as well as B-cell specific
immune response. We have shown that immunisation
with GTU® vectors producing secreted Nef antigen, the
antibodies were raised earlier, at higher level and with
lower doses of the vaccination vector compared to regular
DNA vaccine vectors. The use of GTU® vectors for inducing
of the T-cell immune response against the HIV1 has been
studied in different animal models. These data confirm
that GTU® vector system expressing appropriate antigen
sequences and delivered by the electroporation raise spe-
cific strong and long-lasting T-cell immune response.
Conclusion
Our data suggest that GTU® vector platform is attractive for
development of genetic vaccines against pathogens, like
HIV.
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